Praxis Precision Medicines (PRAX) closed at $277.62 on November 6, 2026, up 5.7% from the previous close, on volume of 268,569 shares (30-day average 473,932).
Data as of November 6, 2026.
6-Nov-2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
BTIG Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)
TipRanks (Mon, 2-Nov 9:43 PM ET)
Globe Newswire (Tue, 27-Oct 4:01 PM ET)
Market Chameleon (Wed, 7-Jan 4:24 AM ET)
Market Chameleon (Fri, 5-Dec 5:29 AM ET)
PRAX Announces Proposed Public Offering as Investors Eye Strategic Funding Move
Market Chameleon (Fri, 17-Oct 6:34 AM ET)
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Praxis Precision Medicines trades on the NASDAQ stock market under the symbol PRAX.
As of November 6, 2026, PRAX stock price climbed to $277.62 with 268,569 million shares trading.
PRAX has a beta of 1.72, meaning it tends to be more sensitive to market movements. PRAX has a correlation of 0.12 to the broad based SPY ETF.
PRAX has a market cap of $7.75 billion. This is considered a Mid Cap stock.
In the last 3 years, PRAX traded as high as $392.70 and as low as $13.01.
The top ETF exchange traded funds that PRAX belongs to (by Net Assets): VTI, VB, IWM, XBI, VBR.
PRAX has outperformed the market in the last year with a price return of +61.1% while the SPY ETF gained +9.6%. However, in the short term, PRAX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -25.0% vs -4.2% return in SPY. But in the last 2 weeks, PRAX shares have fared better than the market returning +9.7% compared to SPY -3.8%.
PRAX support price is $252.99 and resistance is $272.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRAX shares will trade within this expected range on the day.
